Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - finasteride - film-coated tablet - finasteride 5 mg - other dermatological preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - finasteride - film-coated tablet - 5 milligram(s) - testosterone-5-alpha reductase inhibitors; finasteride

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; lactose monohydrate; docusate sodium; sodium starch glycollate type a; titanium dioxide; indigo carmine aluminium lake; hypromellose; macrogol 400 - treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; docusate sodium; titanium dioxide; hypromellose; indigo carmine aluminium lake; macrogol 400 - treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; lauroyl macrogolglycerides; microcrystalline cellulose; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - apo-finasteride 5 is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; lauroyl macrogolglycerides; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; iron oxide red; iron oxide yellow - apo-finasteride 1 is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. apo-finasteride 1 is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; lauroyl macrogolglycerides; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - finapen is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. finapen is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; lauroyl macrogolglycerides; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - finasta is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. finasta is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lauroyl macrogolglycerides; lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - finasta is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Malta - English - Medicines Authority

accord healthcare limited - finasteride - film-coated tablet - finasteride 1 mg - other dermatological preparations